Omkar Speciality Chemicals Ltd.

Omkar Speciality Chemicals Ltd reported zero revenue from operations for the quarter and nine months ended December 31, 2025. The company also posted a net loss of ₹0.33 crore for the quarter and ₹1.26 crore for the nine-month period.

Reader Takeaway: Zero revenue signals no active business, ongoing losses highlight financial fragility.

What just happened

Omkar Speciality Chemicals Ltd. has reported its financial results for the quarter and nine months ending December 31, 2025. For the quarter, the company posted zero revenue from operations and a net loss of ₹0.3284 crore (₹-32.84 lakh). For the nine months ended December 31, 2025, revenue remained at ₹0 crore, with a net loss of ₹1.2562 crore (₹-125.62 lakh).

Why this matters

These results come after the National Company Law Tribunal (NCLT) approved the company's Resolution Plan on July 31, 2025. The company was under Corporate Insolvency Resolution Process (CIRP) since December 5, 2022. The reported zero revenue indicates that business operations have not yet resumed generating income, despite the approval of the resolution plan and a significant capital infusion.

The backstory

The company was admitted to CIRP on December 5, 2022. The NCLT's approval of the resolution plan on July 31, 2025, marked a critical step towards its revival. Following this approval, the management has transitioned to a new board.

What changes now

A new leadership team is in place, with Mr. Dipak Kumar Shaw appointed as the Chief Executive Officer (CEO) and Mr. Ruhini Kumar Chakraborty as an Independent Director. The Resolution Applicant has infused ₹15.0816 crore (₹1,508.16 lakh) up to December 2025 to support the revival. A current bank account has been approved to facilitate daily business operations.

Risks to watch

Key concerns include the complete absence of revenue generation, indicating that business operations are not yet active. The persistent net losses, even with the capital infusion, highlight financial fragility and the need for a successful operational turnaround. The auditors have also noted uncertainty regarding the company's ability to continue as a going concern, although results are prepared on this basis, acknowledging significant recovery challenges.

Governance and Management Changes

As part of the post-CIRP restructuring, the company has appointed Mr. Dipak Kumar Shaw as CEO. Mr. Ruhini Kumar Chakraborty has joined as an Independent Director. R.R. Tibrewala & Co. and Aabid & Co. have been appointed as Statutory and Secretarial Auditors, respectively, for FY 2025-26. Committees such as the Audit Committee and Stakeholder's Relationship Committee have also been formed.

Context metrics (time-bound)

• Capital Infusion: ₹15.0816 crore (₹1,508.16 lakh) infused by the Resolution Applicant up to December 2025.
• Result Period: Quarter and nine months ended December 31, 2025.
• CIRP Start Date: December 5, 2022.
• Resolution Plan Approval Date: July 31, 2025.

What to track next

Investors should closely monitor future announcements regarding the resumption of actual business operations, the effective utilization of the infused capital, and any progress made by the new management team in generating revenue and turning around the company's financial performance.